



SK Biopharmaceuticals to Launch JV with Eurofarma in US for AI Digital Health Solutions

- *SK Biopharmaceuticals, Eurofarma team up to pioneer and accelerate the development and commercialization of seizure prediction AI solutions and digital health ecosystem*
- *The joint venture positions SK Biopharmaceuticals and Eurofarma to capitalize on the rapidly growing digital health sector, further fueling innovation of SK Biopharmaceuticals' flagship epilepsy management platform ZERO*

Seoul, Korea, June 18, 2025 – SK Biopharmaceuticals, a biotech company specializing in R&D and commercialization of treatments for disorders of the central nervous system and oncology worldwide, said that the company agreed to launch in the U.S. a 50-50 joint venture with Eurofarma, focused on further pioneering and advancing seizure prediction AI solutions. The Brazilian pharmaceutical company has a presence in Latin America, Africa and the U.S. and operations across all market segments.

This partnership, announced at the J.P. Morgan Healthcare Conference in San Francisco, California, represents a significant step forward in the development and commercialization of AI-powered digital health technologies designed to improve the lives of patients with epilepsy and related neurological disorders.

The joint venture will prioritize creating cutting-edge digital solutions and platforms that enable epileptic seizure prediction through real-time EEG monitoring, aiming to establish a comprehensive digital health ecosystem tailored to the needs of patients, healthcare providers, and partners. In the mid-to-long term, the partnership plans to expand its offerings to include AI-driven digital solutions capable of identifying, processing, and monitoring biomarkers associated with neuro-psychiatric disorders.

SK Biopharmaceuticals will contribute its intellectual property, including the AI-powered epilepsy management platform ZERO, along with associated R&D assets, while Eurofarma providing financial backing and its digital solutions expertise to support the joint venture's operations and growth.

This collaboration builds on the strong strategic relationship established between the two companies in 2022 when SK Biopharmaceuticals out-licensed its antiseizure medication, cenobamate (U.S. brand name XCOPRI®), to Eurofarma for the development and commercialization in Latin America, starting with Brazil, the region's largest epilepsy market.

The global digital health market is projected to grow from \$180 billion in 2023 to \$550 billion by 2028, with North America accounting for the largest share of the global digital health market.¹

As the joint venture positions SK Biopharmaceuticals and Eurofarma to capitalize on this growth in the rapidly evolving digital health sector, it is expected to accelerate the development and commercialization of ZERO, SK Biopharmaceuticals' flagship epilepsy management platform. With Eurofarma's support in strategy execution and data acquisition, the partnership is well-positioned to drive innovation and improve patient outcomes.

Donghoon Lee, CEO of SK Biopharmaceuticals, said, "The partnership marks a new chapter in the company's global business. We aim to unveil AI-powered epilepsy management solutions in North

America and build this initiative into a cornerstone of our growth in the region.”

###

1. MarketsandMarkets’ “Digital Health Market: Growth, Size, Share, and Trends” (November 2023)

About SK Biopharmaceuticals

SK Biopharmaceuticals focuses on the research, development and commercialization of treatments for disorders of the central nervous system (CNS) and oncology. In 2017, SK Biopharmaceuticals established a research center to begin its expansion into oncology through research and development efforts.

SK Biopharmaceuticals is the first and only Korean company to independently develop and commercialize an antiseizure medication, cenobamate (brand name: XCOPRI®), in the U.S. Cenobamate, which was commercially launched in the U.S. in 2020 by SK Biopharmaceuticals and its U.S. subsidiary SK Life Science, has successfully entered five major regions: North America, Europe, Asia, Central and South America, and the Middle East and North Africa.

The company has a pipeline of eight compounds in development in both CNS disorders and oncology. For more information, visit SK Biopharmaceuticals' website at www.SKBP.com/eng.

About Eurofarma

Established in 1972, Eurofarma operates in the health industry, producing and selling products and services to improve people's quality of life. With a focus on generating shared value, it covers the main pharmaceutical segments, such as prescription, OTC and personal care, generics, hospital, oncology and animal health, as well as providing production services to third parties. With a broad coverage of therapeutic classes, the portfolio comprises more than 2,000 products and 3,700 SKUs (presentations), serving the main medical specialties.

Leader in medical products prescriptions in Latin America, Eurofarma is present in 22 countries with the largest sales force in the region, with coverage of 100% of Latin America countries and operations in the USA and Africa. It has more than 12,600 employees and 11 factories, with total production around 700 million units in the last year. The company invested more than R\$ 700 million in innovation and achieved total net revenue of R\$ 11.1 billion. Over the last 15 years, Eurofarma has recorded average annual growth of 17%.

Media Contacts:

SK Biopharmaceuticals

Julie Kim - jl.k@skbp.com

Eurofarma

Iza França - iza.franca@gaspar.com.br

Guilherme Gaspar - guilherme@gaspar.com.br